Teva Targets $4 Billion Lupus Market With Laquinimod Test

Teva Pharmaceutical Industries Ltd. is planning an advanced study of the experimental drug laquinimod as a treatment for a kidney inflammation caused by lupus after the pill showed promise in a smaller trial.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.